Q3 2024 EPS Estimates for Omnicell, Inc. (NASDAQ:OMCL) Lifted by Analyst

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research raised their Q3 2024 EPS estimates for Omnicell in a research note issued on Tuesday, September 10th. Zacks Research analyst U. Biswas now anticipates that the company will post earnings of $0.17 per share for the quarter, up from their previous forecast of $0.16. The consensus estimate for Omnicell’s current full-year earnings is $0.64 per share. Zacks Research also issued estimates for Omnicell’s Q4 2024 earnings at $0.17 EPS, FY2024 earnings at $0.55 EPS, Q1 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.49 EPS.

OMCL has been the topic of a number of other reports. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. raised their price target on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Wells Fargo & Company upped their price objective on Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Bank of America raised their target price on shares of Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and increased their price objective for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Omnicell currently has an average rating of “Moderate Buy” and an average target price of $37.83.

Omnicell Trading Down 0.4 %

Omnicell stock opened at $43.07 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22. The firm’s 50 day moving average price is $36.77 and its 200-day moving average price is $31.45. Omnicell has a 1 year low of $25.12 and a 1 year high of $56.06. The stock has a market cap of $1.98 billion, a P/E ratio of -93.63, a PEG ratio of 50.19 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. During the same quarter last year, the company earned $0.29 EPS. The firm’s quarterly revenue was down 7.4% on a year-over-year basis.

Hedge Funds Weigh In On Omnicell

Several institutional investors have recently bought and sold shares of OMCL. Nisa Investment Advisors LLC lifted its position in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the last quarter. EntryPoint Capital LLC boosted its position in shares of Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after purchasing an additional 1,345 shares in the last quarter. CWM LLC grew its stake in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after buying an additional 1,236 shares during the last quarter. Benjamin Edwards Inc. grew its stake in Omnicell by 36.4% during the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after buying an additional 868 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Omnicell in the second quarter valued at about $104,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.